Trade Viatris Inc. - VTRS CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.13
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.021512 %(-$4.30)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.02151%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.00071 %(-$0.14)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.00071%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 5.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.021512 %
  (-$4.30)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.00071 %
  (-$0.14)

Key Stats

• Prev. Close: 16.21
• Open: 16.29
• 1-Year Change: 68.63%
• Day's Range: 16.1 - 16.48

Trade Viatris Inc. - VTRS

Viatris (VTRS) is a global healthcare company. It was formed in 2020 through the merger of Pfizer’s (PFE) off-patent branded and generic medicines division Upjohn and pharmaceutical firm Mylan. 

The merger of Mylan and Upjohn was announced in July 2019 and received final regulatory clearance in October 2020. Pfizer shareholders own 57% of Viatris and Mylan shareholders own 43%, according to the merger announcement. Viatris started trading on the Nasdaq Stock Exchange under the ticker VTRS in November 2020. 

Viatris is headquartered in Canonsburg, Pittsburgh, US. The company is operational in over 165 countries and has global centres in Shanghai, China and Hyderabad, India. 

Viatris operates about 40 manufacturing sites which produce oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients. The firm also produces numerous complex generics, biosimilars and global key brands.

Viatris offers treatment options across more than 10 major therapeutic areas covering a wide variety of non-communicable and infectious diseases. According to the company’s website, 50% of its total active pharmaceutical ingredient (API) capacity is devoted to antiretroviral (ARV), which is used against HIV infection. 

Some of the well-known and key brands under Viatris are anxiety treatment drug Xanax, antidepressant Zoloft, anti-inflammatory drug Celebrex and erectile dysfunction therapy Viagra, among others. Viatris also offers global biosimilars franchises focused on the areas of oncology, immunology, endocrinology, ophthalmology and dermatology.